M. Hamadani

发表

Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen

A. Szabo, A. Mato, Raya Saba, 2019, Clinical lymphoma, myeloma & leukemia.

Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.

P. Hari, M. Pasquini, M. Horowitz, 2020, Blood advances.

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation

P. Hari, M. Horowitz, S. Cole, 2018, BMC Cancer.

Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia

Kyle M. Hebert, M. Pasquini, M. Horowitz, 2020, Biology of Blood and Marrow Transplantation.

Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?

F. Jardin, F. Cavalli, E. Zucca, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee

W. Wood, N. Kröger, M. Perales, 2020, Biology of Blood and Marrow Transplantation.

Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas.

S. Usmani, B. Savani, M. Kharfan-Dabaja, 2014, Seminars in hematology.

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

P. Hari, Bryon D Johnson, R. Orentas, 2020, Nature Medicine.

Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

M. Bar, F. Awan, D. Miklos, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma

Bryon D Johnson, M. Hamadani, T. Badar, 2020, Bone Marrow Transplantation.

The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma

N. Rezaei, S. Hanaei, Mahsa Keshavarz-Fathi, 2018, International reviews of immunology.

Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation.

P. Hari, M. Pasquini, M. Horowitz, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy.

M. Perales, A. Nagler, M. Mohty, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non‐MALT Histologies

B. Erickson, P. Hari, M. Siker, 2017, Clinical lymphoma, myeloma & leukemia.

Epidemiology of Food Insecurity in a Nationally Representative Sample of Lymphoma Patients.

M. Hamadani, Taral K Jella, T. Cwalina, 2021, Clinical lymphoma, myeloma & leukemia.

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.

J. Fay, W. Wood, J. Maciejewski, 2018, Leukemia research.

Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis

M. Mohty, Ambuj Kumar, T. Reljic, 2018, Bone Marrow Transplantation.

Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta‐analysis of phase 3 randomized controlled trials

P. Hari, S. Ghose, T. Smunt, 2020, Cancer.

Trends in the use of therapeutic plasma exchange in multiple myeloma

P. Hari, S. Janz, A. Szabo, 2020, Journal of clinical apheresis.

Bronchoalveolar lavage-based COVID-19 testing in patients with cancer

M. Graham, B. George, B. Buchan, 2020, Hematology/Oncology and Stem Cell Therapy.

Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis.

B. Sherrill, A. Abbe, R. Ruiz-Soto, 2015, Clinical lymphoma, myeloma & leukemia.

Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR.

S. Montoto, M. Perales, I. Yakoub-Agha, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome.

P. Hari, M. Pasquini, B. Shaw, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy: Guidelines for Hematopoietic Transplantation and Cellular Therapy.

S. Crawford, P. Veys, R. Champlin, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment of severe mucositis pain with oral ketamine mouthwash

S. Wen, A. Kanate, M. Hamadani, 2016, Supportive Care in Cancer.

Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.

Sonali M. Smith, M. Norkin, D. Maloney, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.

A. Szabo, N. Shah, M. Hamadani, 2019, The oncologist.

Incidence and survival of therapy related myeloid neoplasm in United States.

P. Hari, M. Hamadani, B. Dhakal, 2018, Leukemia research.

A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.

T. Braun, P. Hari, M. Pasquini, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?

Y. Jethava, M. Hamadani, G. S. Guru Murthy, 2017, Hematology/oncology and stem cell therapy.

Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!

B. Savani, M. Kharfan-Dabaja, H. Sibai, 2014, Bone Marrow Transplantation.

Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics

N. Schmitz, S. Montoto, D. Blaise, 2021, Blood advances.

Autologous and Allogeneic Hematopoietic Cell Transplantation for Diffuse Large B-cell Lymphoma-Type Richter Syndrome.

C. Jacobson, Q. Bashir, Z. DeFilipp, 2021, Blood advances.

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis

M. Pasquini, L. Lekakis, V. Bhatt, 2021, Blood advances.

Is Autologous Transplant in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era?

K. Ahn, N. Shah, M. Hamadani, 2020, Blood.

Lower GVHD and relapse risk in PTCy-based Haploidentical vs Matched Sibling Donor RIC Transplant for Hodgkin Lymphoma

M. Aljurf, J. Bolaños-Meade, Y. Nieto, 2019 .

PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.

S. Montoto, D. Blaise, P. Dreger, 2019, Blood advances.

Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation.

P. Hari, M. Pasquini, V. Bachanova, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

J. Vose, Sonali M. Smith, R. Vij, 2018, Cancer.

Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

Sonali M. Smith, S. Devine, S. Jaglowski, 2017, Journal of Hematology & Oncology.

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study

P. Hari, C. Nabhan, N. Ghosh, 2017, Hematological oncology.

Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission.

M. Hamadani, M. Craig, Q. Truong, 2014, Clinical lymphoma, myeloma & leukemia.

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.

S. Montoto, P. Hari, D. Maloney, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase 1/2 trial of Carfilzomib plus High Dose Melphalan Preparative Regimen for Salvage AHCT Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma

Giralt, P. Hari, H. Landau, 2020 .

Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.

P. Hari, S. Giralt, H. Landau, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas.

P. Hari, M. Hamadani, T. Fenske, 2015, World journal of transplantation.

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.

H. Lazarus, B. Cooper, T. Kindwall‐Keller, 2015, Clinical lymphoma, myeloma & leukemia.

Phase I study of midostaurin and azacitidine in relapsed and elderly AML.

H. Lazarus, B. Cooper, T. Kindwall‐Keller, 2013 .

A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine

M. Hamadani, N. Epperla, 2021, Current Hematologic Malignancy Reports.

Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes.

M. Pasquini, Stephanie J. Lee, B. Shaw, 2022, Transplantation and cellular therapy.

Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.

S. Montoto, P. Hari, D. Maloney, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

C. Carlo-Stella, P. Caimi, M. Hamadani, 2022, Clinical lymphoma, myeloma & leukemia.

Role of intra‐arterial steroid administration in the management of steroid‐refractory acute gastrointestinal graft‐versus‐host disease

A. Tfayli, M. Hamadani, G. Selby, 2006, American journal of hematology.

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome

H. Deeg, D. Porter, G. Gui, 2020, medRxiv.

BMT CTN State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

E. Leifer, P. Hari, H. Heslop, 2021, Transplantation and cellular therapy.

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.

P. Riedell, L. Gordon, A. D’Andrea, 2022, The Lancet. Oncology.

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.

J. Radford, S. Horwitz, J. Wuerthner, 2021, The Lancet. Haematology.

Enteropathy-Associated T cell Lymphoma

M. Aljurf, R. El Fakih, M. Kharfan-Dabaja, 2021, Current Hematologic Malignancy Reports.

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

K. Ardeshna, M. Lunning, P. Caimi, 2021, Clinical Lymphoma Myeloma and Leukemia.

Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression

P. Hari, John M. Astle, M. Hamadani, 2020, British journal of haematology.

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

J. Radford, K. Ardeshna, O. O’Connor, 2019, Clinical Cancer Research.

R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis

J. Vose, N. Ghosh, A. Szabo, 2018, British journal of haematology.

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

P. Hari, S. Mineishi, P. Armand, 2017, Blood.

WBMT Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy.

I. Yakoub-Agha, M. Mohty, M. Aljurf, 2022, Transplantation and Cellular Therapy.

Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014

P. Hari, M. Pasquini, A. D’Souza, 2017, Leukemia.

Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?

M. Hamadani, 2021, Haematologica.

Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL)

S. Wen, A. Kanate, M. Hamadani, 2017, Bone Marrow Transplantation.

Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome.

A. Banerjee, P. Hari, M. Pasquini, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy

C. Flowers, K. Blum, J. Maly, 2018, Cancer.

CD103 Deficiency Prevents Graft-versus-Host Disease but Spares Graft-versus-Tumor Effects Mediated by Alloreactive CD8 T Cells

S. Devine, Jiao-jing Wang, A. Gaughan, 2011, PloS one.

Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy‐era with plerixafor and G‐CSF has superior efficacy but significantly higher costs compared to mobilization with low‐dose cyclophosphamide and G‐CSF

F. Awan, K. Watkins, W. Tse, 2013, Journal of clinical apheresis.

Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies

F. Awan, K. Watkins, M. Hamadani, 2013, Bone Marrow Transplantation.

Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.

F. Awan, K. Watkins, M. Hamadani, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.

A. Szabo, A. Cashen, N. Shah, 2019, Blood advances.

Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.

M. Hamadani, N. Epperla, 2021, Hematology. American Society of Hematology. Education Program.

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.

Sonali M. Smith, A. Zelenetz, J. Friedberg, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.

E. Leifer, N. Geller, D. Porter, 2021, Transplantation and cellular therapy.

Extended follow‐up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit

J. Abraham, M. Hamadani, A. Sarwari, 2013, Transplant infectious disease : an official journal of the Transplantation Society.

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.

Alan M. Miller, M. Norkin, P. Hari, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis

P. Hari, M. Pasquini, D. Weihrauch, 2017, Contemporary clinical trials communications.

The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation.

F. Awan, S. Devine, M. Hamadani, 2008, Blood.

Lymphoma: working committee and data reporting after transplantation in lymphoma

P. Hari, S. Hashmi, W. Saber, 2015 .

Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.

J. Vose, M. Aljurf, R. Gale, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.

C. Hofmeister, R. Garzon, G. Marcucci, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High‐dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B‐cell lymphoma

K. Blum, P. Porcu, S. Devine, 2008, European journal of haematology.

Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma

F. Awan, K. Blum, P. Porcu, 2008, Leukemia & lymphoma.

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

A. Krishnan, W. Wood, P. Hari, 2015, Bone Marrow Transplantation.

SAR245409 Monotherapy in relapsed/refractory follicular lymphoma: preliminary results from the phase II ARD12130 study

M. Kersten, M. Millenson, H. Tilly, 2013 .

Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?

F. Awan, A. Tfayli, H. Ozer, 2007, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Rituximab maintenance versus retreatment in follicular lymphoma

M. Hamadani, Amruth R. Palla, 2013, Hematological oncology.

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

P. Richardson, H. van de Velde, A. Di Bacco, 2017, Haematologica.

Malignant thymoma with immunodeficiency (Good syndrome) associated with mucormycosis.

F. Awan, M. Villalona-Calero, M. Hamadani, 2010, American journal of clinical oncology.

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

C. Flowers, K. Blum, N. Ghosh, 2021, Blood advances.

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy.

K. Ardeshna, C. Carlo-Stella, P. Caimi, 2020, Blood advances.

Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas

Ibrahim N. Muhsen, M. Aljurf, H. Lazarus, 2022, Clinical Hematology International.

Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma

M. Perales, K. Ahn, J. Zain, 2022, British journal of haematology.

Controversies and Recent Advances in Hematopoietic Cell Transplantation for Follicular Non-Hodgkin Lymphoma

M. Kharfan-Dabaja, A. Kanate, M. Hamadani, 2012, Bone marrow research.

Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT.

A. Szabo, Saira S Ahmed, A. Cashen, 2020, Blood advances.

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

M. Horowitz, M. Hamadani, 2017, Journal of oncology practice.

Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis

A. Abbe, R. Ruiz-Soto, P. Trask, 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Indications for Allogeneic Hematopoietic Stem Cell Transplantation in Adults

M. Horowitz, M. Hamadani, N. Epperla, 2018 .

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

B. Sandmaier, M. Aljurf, R. Gale, 2016, Cancer.

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Sonali M. Smith, N. Kröger, P. Hari, 2015, Bone Marrow Transplantation.

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

E. Leifer, N. Geller, H. Deeg, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management Strategies for Follicular Lymphoma patients in Remission after Modern Frontline Chemoimmunotherapies

M. Hamadani, L. Chaudhary, 2013 .

What is the standard of care for primary mediastinal B cell lymphoma; R‐CHOP or DA‐EPOCH‐R? – Response to Melani et al

J. Svoboda, N. Shah, M. Hamadani, 2019, British journal of haematology.

Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis.

Sonali M. Smith, P. Hari, J. Bolaños-Meade, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children (<18y) and Young adults (18–29y) with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis

W. Wood, R. Sparapani, R. Gale, 2016 .

Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease

M. Hamadani, S. Abedin, 2020, Expert opinion on investigational drugs.

Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect.

F. Awan, K. Blum, S. Devine, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review.

Ambuj Kumar, T. Reljic, M. Kharfan-Dabaja, 2016, Future oncology.

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.

S. Montoto, Sonali M. Smith, P. Hari, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T-Cell Lymphomas As Front-Line Consolidation or in the Relapsed/Refractory Setting: A Meta-Analysis

Ambuj Kumar, T. Reljic, M. Kharfan-Dabaja, 2015 .

MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR)

C. Flowers, K. Blum, P. Martin, 2019, Hematological Oncology.

Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma

C. Flowers, K. Blum, J. Maly, 2018, Leukemia & lymphoma.

Incidence and survival trends in mantle cell lymphoma

L. Costa, M. Hamadani, T. Fenske, 2018, British journal of haematology.

Ibrutinib in Refractory Classic Hodgkin's Lymphoma.

P. Hari, M. Hamadani, S. Balasubramanian, 2015, The New England journal of medicine.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Alan M. Miller, Sonali M. Smith, R. Vij, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity allografting as first transplantation approach in relapsed/refractory grade 1-2 follicular lymphoma provides improved outcomes in long-term survivors Biol Blood Marrow Transplant

Alan M. Miller, Sonali M. Smith, R. Vij, 2015 .

The evolving role of statins in hematopoietic stem and progenitor cell transplantation.

S. Remick, L. Gibson, M. Hamadani, 2011, American journal of blood research.

Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer

A. Harrington, S. Kroft, M. Hamadani, 2016, Bone Marrow Transplantation.

Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis.

P. Hari, M. Pasquini, R. Brazauskas, 2017, Hematology/oncology and stem cell therapy.

Gastrointestinal chronic graft-versus-host disease: management options

F. Awan, M. Hamadani, 2007, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.

P. Hari, M. Pasquini, M. Horowitz, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.

W. Petros, S. Remick, L. Gibson, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.

C. Hofmeister, G. Phillips, G. Marcucci, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease

M. Hamadani, S. Abedin, 2020, Journal of experimental pharmacology.

Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease

P. Hari, M. Pasquini, M. Horowitz, 2018, Haematologica.

FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?

M. Horowitz, Richard J. Jones, M. Levis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol

Carol L. Williams, P. Hari, A. Szabo, 2022, The Yale journal of biology and medicine.

Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T‐cells

P. Hari, Bryon D Johnson, A. Szabo, 2022, American journal of hematology.

Systemic Anaplastic Lymphoma Kinase‐positive Anaplastic Large Cell Lymphoma: A Population‐based Analysis of Incidence and Survival

V. Bhatt, P. Mehta, M. Hamadani, 2017, Clinical lymphoma, myeloma & leukemia.

Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis

P. Hari, M. Pasquini, R. Brazauskas, 2015, American journal of hematology.

Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma

M. Hamadani, N. Ahmed, Nausheen Ahmed, 2021, Expert review of anticancer therapy.

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

Alan M. Miller, R. Vij, M. Aljurf, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

An updated single center experience with plerixafor and granulocyte colony‐stimulating factor for stem cell mobilization in light chain amyloidosis

P. Hari, Bryon D Johnson, A. Szabo, 2019, Journal of clinical apheresis.

Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia

G. Phillips, J. Szer, M. Kalaycio, 2010, British journal of haematology.

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

E. Leifer, N. Geller, H. Deeg, 2015 .

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data

M. Hamadani, F. Furqan, 2022, Therapeutic advances in hematology.

Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.

P. Hari, M. Pasquini, A. D’Souza, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation

Sonali M. Smith, M. Perales, Q. Bashir, 2016, British journal of haematology.

Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia: No Impact of Pre-transplant Extramedullary Disease on Outcome

M. Tallman, R. Gale, T. Shea, 2015, Bone Marrow Transplantation.

Improved non-relapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced intensity conditioning allogeneic transplantation for hematologic malignancies

J. Byrd, R. Garzon, G. Phillips, 2014 .

Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.

P. Hari, R. Gale, M. Cairo, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.

J. Abraham, S. Remick, L. Gibson, 2011, Hematology/oncology and stem cell therapy.

Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.

J. Byrd, C. Hofmeister, R. Garzon, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation.

R. Mahfouz, H. Lazarus, M. Kharfan-Dabaja, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.

M. Robin, G. Garcia-Manero, Z. DeFilipp, 2022, Transplantation and cellular therapy.

Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival

C. Flowers, K. Blum, J. Switchenko, 2021, European journal of haematology.

Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis

P. Hari, M. Pasquini, A. D’Souza, 2015, Bone Marrow Transplantation.

Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis.

P. Hari, M. Pasquini, A. D’Souza, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations.

P. Hari, M. Mohty, M. Aljurf, 2020, Hematology/oncology and stem cell therapy.

Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations.

P. Hari, M. Mohty, M. Aljurf, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post‐relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation

F. Awan, B. Christian, M. Qazilbash, 2021, Hematological oncology.

Utilization and cost implications of hematopoietic progenitor cells stored for a future salvage autologous transplantation or stem cell boost in myeloma patients.

P. Hari, M. Pasquini, Bryon D Johnson, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.

P. Hari, M. Pasquini, A. D’Souza, 2016, Clinical lymphoma, myeloma & leukemia.

Impact of treatment and outcomes for patients with posttransplant drug‐associated thrombotic microangiopathy

K. Friedman, M. Hamadani, N. Epperla, 2017, Transfusion.

Relapse after allogeneic hematopoietic cell transplantation for multiple myeloma: Survival outcomes and factors influencing them.

P. Hari, M. Pasquini, A. Szabo, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Advances in transplantation for lymphomas resulting from CIBMTR lymphoma working committee's research portfolio: A five‐year report (2013‐2018)

M. Hamadani, 2018, Advances in cell and gene therapy.

Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular iymphoma

S. Montoto, M. Pasquini, P. Dreger, 2018, Cancer.

Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?

S. Montoto, M. Pasquini, P. Dreger, 2020 .

Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization

F. Awan, M. Hamadani, M. Craig, 2012, Journal of oncology.

Alpha‐1‐antitrypsin for the treatment of steroid‐refractory acute gastrointestinal graft‐versus‐host disease

P. Hari, M. Pasquini, B. Shaw, 2017, American journal of hematology.

Allogeneic haematopoietic cell transplantation for extranodal natural killer/T‐cell lymphoma, nasal type: a CIBMTR analysis

Sonali M. Smith, M. Perales, E. Jacobsen, 2018, British journal of haematology.

The Evolution of Our Understanding of Immunoproliferative Small Intestinal Disease (IPSID) over Time

M. Aljurf, M. Kharfan-Dabaja, M. Hamadani, 2022, Current oncology.

LOTIS 2 FOLLOW-UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

J. Radford, P. Zinzani, K. Ardeshna, 2021 .

Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective

P. Hari, M. Pasquini, B. Shaw, 2018, Bone Marrow Transplantation.

Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study

D. Blaise, P. Dreger, Stephanie J. Lee, 2021, Blood.

Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein–Barr virus DNA PCR

C. Hofmeister, D. Benson, S. Devine, 2007, Bone Marrow Transplantation.

Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients.

R. Kamble, M. Hamadani, G. Selby, 2006, The Journal of antimicrobial chemotherapy.

Current Use and Trends in Hematopoietic Cell Transplantation in the United States.

P. Hari, M. Pasquini, M. Horowitz, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

P. Hari, N. Ledeboer, M. Hamadani, 2021, Blood.

ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.

M. Perales, A. Nagler, M. Mohty, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.

W. Wood, R. Sparapani, R. Gale, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

H. Deeg, D. Porter, G. Gui, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

Benjamin Djulbegovic, Ambuj Kumar, Mehdi Hamadani, 2013, Journal of Hematology & Oncology.

Paraneoplastic Sweet’s syndrome and the pathergy phenomenon

F. Awan, S. Devine, M. Hamadani, 2007, Annals of Hematology.

Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies

S. Wen, A. Kanate, M. Hamadani, 2015, Antimicrobial Agents and Chemotherapy.

Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis.

M. Hamadani, D. Slain, M. Craig, 2012, International journal of antimicrobial agents.

Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Commi

W. Wood, N. Kröger, M. Perales, 2020, Biology of Blood and Marrow Transplantation.

Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients

A. Kanate, M. Hamadani, M. Craig, 2014, Annals of Hematology.

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.

M. Bar, J. Wagner, J. Sierra, 2021, Transplantation and cellular therapy.

Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis

M. Horowitz, B. Shaw, S. Devine, 2020, Biology of Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

L. Lekakis, N. Ghosh, H. Lazarus, 2019, Journal of Hematology & Oncology.

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

R. Advani, A. Nademanee, J. Friedberg, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Granulocytic Sarcoma Manifesting as Multiple Skeletal Lesions

A. Tfayli, M. Hamadani, S. Sethi, 2005, The American journal of the medical sciences.

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL

B. Savani, M. Hamadani, M. Iqbal, 2021, EJHaem.

Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies

B. Savani, M. Hamadani, S. Chhabra, 2021, British journal of haematology.

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis.

H. Chu, D. Weisdorf, A. Rashidi, 2019, Blood advances.

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015

M. Norkin, W. Wood, J. Wingard, 2015, Bone Marrow Transplantation.

The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia

W. Blum, M. Hamadani, 2009 .

Hematopoietic stem cell transplantation in adults with acute myeloid leukemia.

F. Awan, E. Copelan, M. Hamadani, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Evaluation of children with malignancies for blood and marrow transplantation: A report from the ASTCT Committee on Practice Guidelines.

M. Kohorst, H. Stefanski, M. Qayed, 2023, Transplantation and cellular therapy.

Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients

R. Turner, W. Petros, S. Wen, 2016, Antimicrobial Agents and Chemotherapy.

Thalidomide-induced fulminant hepatic failure.

D. Benson, E. Copelan, M. Hamadani, 2007, Mayo Clinic proceedings.

Autologous hematopoietic cell transplantation: An update for clinicians

M. Hamadani, 2014, Annals of medicine.

First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.

R. Advani, J. Bendell, P. Munster, 2021 .

Current state of hematopoietic cell transplantation in CLL as smart therapies emerge.

F. Awan, M. Kharfan-Dabaja, M. Hamadani, 2016, Best practice & research. Clinical haematology.

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis.

A. Krishnan, S. Lonial, R. Vij, 2011, Blood.

Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.

R. Vij, P. Hari, M. Perales, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.

R. Advani, D. Siegel, D. Juric, 2022, Journal of Clinical Oncology.

Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.

P. Hari, M. Pasquini, N. Shah, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Regulation of acute graft-versus-host disease by microRNA-155.

M. Caligiuri, J. Byrd, C. Croce, 2010, Blood.

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

Neeraj Gupta, Eileen Liao, Parameswaran Hari, 2014, The Lancet. Oncology.

Haploidentical Hematopoietic Cell Transplantation in Lymphomas

P. Hari, M. Hamadani, G. Murthy, 2018 .

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.

Shannon R. McCurdy, M. Perales, R. Soiffer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

Sonali M. Smith, P. Hari, P. Armand, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis

L. Castagna, Fei Wan, M. Arango, 2021, Bone Marrow Transplantation.

Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?

M. Hamadani, T. Fenske, N. Epperla, 2015, Bone Marrow Transplantation.

A Prognostic Model Predicting Autologous Transplantation Outcomes in Children, Adolescents and Young Adults with Hodgkin Lymphoma

J. Vose, Sonali M. Smith, W. Wood, 2015, Bone Marrow Transplantation.

Preparative regimens for lymphoma

M. Kharfan-Dabaja, M. Hamadani, E. Ayala, 2015 .

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.

J. Radford, P. Zinzani, K. Ardeshna, 2021, The Lancet. Oncology.

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

P. Riedell, F. Awan, M. Krem, 2021, JAMA oncology.

Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can.

S. Devine, M. Hamadani, 2009, Blood.

CAR T-cell therapy for secondary CNS DLBCL

N. Shah, M. Hamadani, Gulrayz Ahmed, 2021, Blood advances.

Cellular immunotherapy for refractory DLBCL in the CART era: still a role for allogeneic transplantation?

S. Montoto, M. Pasquini, P. Dreger, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor.

K. Blum, B. Christian, Weiqiang Zhao, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

Lisa L. Smith, J. Byrd, A. Johnson, 2009, Leukemia & lymphoma.

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

Lisa L. Smith, J. Byrd, A. Johnson, 2009 .

Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations.

M. Kharfan-Dabaja, M. Hamadani, T. Nishihori, 2016, Immunotherapy.

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide.

Shannon R. McCurdy, M. Norkin, M. Perales, 2018, Blood advances.

A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem-cell Transplant.

P. Voorhees, N. Ghosh, E. Copelan, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

P. Hari, S. Tarima, A. D’Souza, 2021, Clinical lymphoma, myeloma & leukemia.

Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis

P. Hari, B. Shaw, A. Szabo, 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Sonali M. Smith, M. Perales, R. Gale, 2016, Blood.

Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft

P. Hari, M. Pasquini, M. Horowitz, 2017, Bone Marrow Transplantation.

Higher total body irradiation dose-intensity in fludarabine/TBI-based reduced-intensity conditioning regimen is associated with inferior survival in non-Hodgkin lymphoma patients undergoing allogeneic transplantation: Flu/2Gy TBI vs Flu/4Gy TBI in NHL.

F. Awan, K. Ahn, R. Karmali, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation.

P. Hari, M. Pasquini, A. Szabo, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pulmonary Nocardia and Aspergillus co‐infection in a patient with chronic graft‐versus‐host disease

D. Benson, S. Devine, W. Blum, 2008, Transplant infectious disease : an official journal of the Transplantation Society.

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients

N. Ledeboer, A. D’Souza, N. Shah, 2022, Cancer Cell.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis

B. Gyawali, P. Hari, A. Szabo, 2018, JAMA oncology.

Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.

S. Wen, K. Watkins, A. Kanate, 2015, Cytotherapy.

Randomized Multicenter Trial of Sirolimus vs. Prednisone as Initial Therapy for Standard Risk Acute GVHD: BMT CTN 1501.

E. Leifer, M. Horowitz, J. Pidala, 2019, Blood.

Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study

J. Radford, K. Ardeshna, O. O’Connor, 2018, Blood.

Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT

M. Norkin, W. Wood, J. Snowden, 2016, Bone Marrow Transplantation.

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan‐based reduced toxicity conditioning

C. Hofmeister, R. Garzon, G. Phillips, 2011, Hematological oncology.

Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

J. Wuerthner, K. Havenith, J. Boni, 2020, Blood.

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

S. Horwitz, J. Wuerthner, J. Boni, 2018, Blood.

Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.

P. Hari, M. Pasquini, B. Shaw, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dramatic response to single‐agent rituximab in a patient with intravascular lymphoma

S. Suster, F. Awan, M. Hamadani, 2007, American journal of hematology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation.

P. Hari, S. Pingali, Asmita R Patel, 2016, Clinical lymphoma, myeloma & leukemia.

Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances.

M. Hamadani, N. Epperla, 2017, Hematology/oncology and stem cell therapy.

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

A. Evens, E. Petersdorf, H. Lazarus, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT

J. Vose, S. Montoto, Sonali M. Smith, 2019, JAMA oncology.

Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?

P. Hari, M. Kharfan-Dabaja, M. Hamadani, 2013, Bone Marrow Transplantation.

Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?

M. Hamadani, 2013, Bone Marrow Transplantation.

Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges

P. Hari, S. Usmani, M. Hamadani, 2020, Bone Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.

J. Cortes, M. Aljurf, M. Tallman, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis.

Ambuj Kumar, T. Reljic, M. Kharfan-Dabaja, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

J. Gribben, E. Montserrat, F. Awan, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.

P. Hari, M. Pasquini, A. Kanate, 2014, World journal of stem cells.

Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia

F. Awan, M. Hamadani, 2009, Hematological oncology.

ASTCT Clinical Practice recommendations for transplant and cellular therapies in multiple myeloma.

H. Einsele, S. Lonial, M. Mohty, 2022, Transplantation and cellular therapy.

BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML

M. Horowitz, M. Levis, Yi-Bin Chen, 2019, Blood.

Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.

J. Cortes, M. Aljurf, J. Szer, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

J. Cortes, M. Aljurf, J. Szer, 2013, Blood.

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis

Sonali M. Smith, R. Vij, W. Wood, 2019, Blood Cancer Journal.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

J. Mehta, M. Perales, N. Saba, 2019, Clinical Cancer Research.

Risk Factors for Cost-Related Delays to Medical Care Among Lymphoma Patients: A 22-Year Analysis of a Nationally Representative Sample.

J. Treisman, M. Hamadani, T. Cwalina, 2021, Clinical lymphoma, myeloma & leukemia.

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

M. Kersten, M. Millenson, H. Tilly, 2018, The Lancet. Haematology.

Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas

A. Kanate, M. Hamadani, 2013 .

Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells.

J. Dipersio, M. Horowitz, Yi-Bin Chen, 2019, Blood advances.

Cellular Therapies for Mantle Cell Lymphoma.

J. Chavez, M. Kharfan-Dabaja, M. Hamadani, 2021, Transplantation and cellular therapy.

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

J. Vose, S. Montoto, Sonali M. Smith, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Multi‐center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era

C. Flowers, K. Blum, N. Ghosh, 2021, American journal of hematology.

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma

P. Hari, M. Pasquini, A. D’Souza, 2019, Blood Cancer Journal.

Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphoma

W. Wood, Z. DeFilipp, B. Shaw, 2018, Cancer.

with TBI following cyclophosphamide in combination with busulfan compared Better leukemia-free and overall survival in AML in first remission

J. Cortes, M. Aljurf, J. Szer, 2013 .

Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature.

R. Kamble, H. Ozer, M. Kharfan-Dabaja, 2006, The Journal of the Oklahoma State Medical Association.

Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes

P. Hari, A. D’Souza, E. Cohen, 2015, Bone Marrow Transplantation.

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.

M. Mohty, M. Kharfan-Dabaja, M. Hamadani, 2011, Cancer control : journal of the Moffitt Cancer Center.

A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

A. Hui, S. Lonial, P. Richardson, 2011 .

Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.

M. Pasquini, A. D’Souza, N. Shah, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fibrous dysplasia protuberans in a patient with McCune-Albright syndrome.

M. Hamadani, B. Brown, A. Awab, 2006, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT

M. Norkin, A. Nagler, J. Szer, 2018, Bone Marrow Transplantation.

Breast Implant-associated Anaplastic Large Cell Lymphoma.

M. Aljurf, Mubarak M. Al-Mansour, M. Hamadani, 2020, Clinical lymphoma, myeloma & leukemia.

Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study

P. Hari, J. Perkins, J. Lipton, 2017, British journal of haematology.

Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies.

P. Hari, A. Szabo, A. D’Souza, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.

Sonali M. Smith, P. Armand, S. Jaglowski, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies.

D. Miklos, F. Galimi, S. Neelapu, 2022, Journal of Clinical Oncology.

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

S. de Vos, D. Miklos, L. Lekakis, 2021, Blood.

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma

F. Awan, M. Perales, C. Jacobson, 2022, Haematologica.

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.

P. Hari, N. Shah, M. Hamadani, 2022, JAMA oncology.

Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission.

C. Turtle, M. Pasquini, F. Locke, 2021, Blood.

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, K. Ardeshna, 2020 .

Impact of reduced-intensity conditioning regimens on outcomes in diffuse large B-cell lymphoma undergoing allogeneic transplantation.

N. Ghosh, K. Ahn, A. Sureda, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.

P. Riedell, Sonali M. Smith, F. Locke, 2021, Transplantation and cellular therapy.

Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation.

M. Mohty, Z. Otrock, M. Kharfan-Dabaja, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Matthew J. Frigault, R. Houot, V. Torri, 2021, Leukemia.

Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR

S. Montoto, Sonali M. Smith, M. Pasquini, 2018, Cancer.

ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after failure of Chimeric antigen receptor T cell therapy (CAR-T) therapy.

M. Perales, Z. DeFilipp, S. Hashmi, 2022, Transplantation and cellular therapy.

ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma.

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Bone Marrow Transplantation.

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Transplantation and cellular therapy.

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis.

Sonali M. Smith, Z. DeFilipp, H. Lazarus, 2018, Blood advances.

Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies

Zheng Zhou, C. Flowers, A. Evens, 2017, American journal of hematology.

Pediatric‐inspired therapy compared to allografting for Philadelphia chromosome‐negative adult ALL in first complete remission

D. Neuberg, S. Sallan, J. Bergeron, 2016, American journal of hematology.

Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections

P. Hari, M. Pasquini, B. Shaw, 2016, Bone Marrow Transplantation.

Severity of cytokine release syndrome and its association with infections after T-cell replete haploidentical related donor transplantation.

M. Graham, P. Hari, M. Pasquini, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Diffuse large B‐cell lymphoma

B. Savani, M. Kharfan-Dabaja, A. Kanate, 2015 .

Autologous hematopoietic cell transplantation versus whole‐brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta‐analysis

S. Chowdhury, Ambuj Kumar, T. Reljic, 2022, Hematological oncology.

Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

M. Aljurf, R. Gale, L. Lekakis, 2020, Cancer.

How we approach patient evaluation for hematopoietic stem cell transplantation

F. Awan, S. Devine, M. Hamadani, 2010, Bone Marrow Transplantation.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

S. Montoto, Sonali M. Smith, J. Klein, 2015, Biology of Blood and Marrow Transplantation.

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

P. Zinzani, N. Bartlett, J. Kuruvilla, 2022, Leukemia & lymphoma.

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

A. Harrington, M. Hamadani, L. Michaelis, 2019, Blood.

Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study

M. Hamadani, L. Michaelis, K. Carlson, 2021, Blood.

Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?

B. Savani, M. Kharfan-Dabaja, A. Kanate, 2017, Bone Marrow Transplantation.

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.

P. Hari, R. Gale, Y. Nieto, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

M. Perales, Richard J. Jones, Y. Efebera, 2022, Blood.

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.

A. Krishnan, R. Vij, P. Hari, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin

M. Regier, W. Tse, M. Hamadani, 2013, Bone marrow research.

Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.

H. Deeg, D. Porter, J. Cortes, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

M. Pasquini, J. Wingard, K. Ballen, 2019, Blood advances.

Fludarabine/busulfan conditioning based allogeneic hematopoietic cell transplantation for myelofibrosis: Role of ruxolitinib in improving survival outcomes.

P. Hari, M. Pasquini, B. Shaw, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT

Hamadani, M. Norkin, W. Wood, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

Shannon R. McCurdy, M. Perales, M. Horowitz, 2016 .

Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals.

P. Hari, M. Pasquini, A. Szabo, 2019, JAMA network open.

Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the Center for International Blood and Marrow Transplant Research.

M. Pasquini, B. Shaw, K. Flynn, 2023, Transplantation and cellular therapy.

Haploidentical versus matched unrelated donor transplants using post-transplant cyclophosphamide for lymphomas.

D. Blaise, P. Dreger, Stephanie J. Lee, 2022, Transplantation and cellular therapy.

Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

M. Perales, A. Kanate, M. Hamadani, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

S. Lonial, J. Laubach, P. Richardson, 2019, Leukemia.

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age

P. Hari, A. D’Souza, M. Hamadani, 2017, Clinical lymphoma, myeloma & leukemia.

The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma.

C. Hofmeister, E. Hade, D. Benson, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.

B. Sandmaier, M. Perales, A. Nagler, 2020, Blood advances.

Myeloablative vs. reduced-intensity hematopoietic cell transplantation in myelodysplastic syndromes: a systematic review and meta-analysis.

H. Chu, M. Pasquini, S. Devine, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.

M. Perales, M. Aljurf, Y. Nieto, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.

A. Krishnan, P. Hari, Y. Nieto, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

M. Aljurf, J. Szer, R. Gale, 2020 .

Higher Total Body Irradiation (TBI) Dose-Intensity in Fludarabine (Flu)/TBI-Based Reduced-Intensity Conditioning (RIC) Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma (NHL) Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT).

K. Ahn, M. Kharfan-Dabaja, M. Hamadani, 2020 .

Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.

M. Aljurf, L. Lekakis, N. Ghosh, 2020, JAMA oncology.

Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma

B. Djulbegovic, R. Mhaskar, Ambuj Kumar, 2016 .

Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes.

K. Watkins, A. Kanate, M. Hamadani, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta‐analysis

B. Djulbegovic, J. Lancet, H. Fernandez, 2013, British journal of haematology.

The impact of post-hematopoietic stem cell transplant tyrosine kinase inhibitors in Philadelphia-positive acute lymphoblastic leukemia.

M. Hamadani, D. Al Rimawi, K. Halahleh, 2021, Hematology/oncology and stem cell therapy.

A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML.

M. Levis, Yi-Bin Chen, S. Devine, 2018 .

Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR

R. Larson, B. Sandmaier, F. Appelbaum, 2021, Leukemia.

Impact of type of reduced‐intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma

N. Ghosh, M. Cairo, U. Farooq, 2020, British journal of haematology.

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

M. Pasquini, J. Wingard, K. Ballen, 2018, Blood.

Impact of conditioning regimen intensity on the outcomes of peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma patients undergoing allogeneic transplant

K. Ahn, M. Shadman, C. Cutler, 2022, British journal of haematology.

Early detection of digitalis-induced nonocclusive mesenteric ischemia using Doppler ultrasonography.

T. Whitsett, M. Hamadani, S. Saya, 2006, Southern medical journal.

Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

J. Radford, K. Ardeshna, O. O’Connor, 2020, Blood.

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

Michael L. Wang, I. Lossos, C. Reeder, 2017, Journal of Hematology & Oncology.

OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCING FRONTLINE TREATMENT FAILURE: A MULTICENTER RETROSPECTIVE STUDY

C. Flowers, K. Blum, P. Martin, 2019, Hematological Oncology.

Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation

J. Vose, P. Riedell, Sonali M. Smith, 2021, British journal of haematology.

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin

Zheng Zhou, C. Flowers, A. Evens, 2018, Leukemia & lymphoma.

C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy

Zheng Zhou, C. Flowers, F. Hernandez-Ilizaliturri, 2017, Cancer.

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

J. Radford, K. Ardeshna, A. Stathis, 2022, Blood advances.

Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B‐cell lymphomas in first remission in the rituximab era: A systematic review and meta‐analysis

B. Savani, Ambuj Kumar, T. Reljic, 2019, Cancer.

Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma

F. Awan, Hamza Hashmi, M. Hamadani, 2018, Expert opinion on pharmacotherapy.

Outcomes of autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma refractory to first line chemoimmunotherapy.

L. Costa, M. Hamadani, C. Sauter, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma

K. Havenith, J. Boni, P. Caimi, 2022, Cancer Chemotherapy and Pharmacology.

Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma

J. Boni, P. Caimi, M. Hamadani, 2022, Cancer Chemotherapy and Pharmacology.

ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT‐301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)

J. Radford, S. Horwitz, J. Wuerthner, 2019, Hematological Oncology.

Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit.

M. Hamadani, M. Craig, Michael Sweet, 2012, American journal of infection control.

Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation.

P. Hari, M. Pasquini, Carolyn J Oxencis, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prospective, Multicenter Clinical Trial of Atorvastatin-Based Acute Graft-Versus-Host-Disease (aGVHD) Prophylaxis in Recipients of HLA-Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplantation (alloHCT)

P. Hari, M. Pasquini, M. Horowitz, 2016 .

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

S. Horwitz, J. Boni, A. Spira, 2017 .

Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination

Nicholas R. Waters, P. Hari, M. V. D. van den Brink, 2022, medRxiv.

Maintenance tyrosine kinase inhibitors following allo-HCT for chronic myeloid leukemia: A CIBMTR Study.

M. Aljurf, J. Szer, R. Gale, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Parameswaran Hari, Mehdi Hamadani, Dina Schneider, 2018, Blood.

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

P. Hari, P. Armand, L. Andritsos, 2016 .

Autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (MM) in the era of novel agents: A meta-analysis of phase III randomized controlled trials.

P. Hari, J. Jackson, S. Usmani, 2017 .

Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation

P. Hari, S. Pingali, R. Karmali, 2017, Clinical lymphoma, myeloma & leukemia.

A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML

A. Harrington, M. Hamadani, L. Michaelis, 2020 .

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy

N. Shah, M. Hamadani, T. Fenske, 2022, Blood advances.

Reality check: Real-world evidence to support therapeutic development in hematologic malignancies.

H. Lazarus, M. Battiwalla, M. Hamadani, 2022, Blood reviews.

ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, K. Ardeshna, 2021 .

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation

P. Hari, M. Horowitz, S. Cole, 2018, BMC cancer.

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation

F. Awan, J. Abraham, S. Remick, 2012, Bone Marrow Transplantation.

Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients

T. Braun, P. Hari, M. Pasquini, 2017 .

Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant

C. Flowers, K. Blum, N. Ghosh, 2019, Blood.

Role of CD19 CAR T Cells in Second Line Large B Cell Lymphoma: Lessons from Phase 3 Trials - An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

M. Perales, O. Oluwole, T. Jain, 2022, Transplantation and cellular therapy.

Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT)

S. Lonial, J. Laubach, P. Richardson, 2017 .

Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.

P. Richardson, P. Moreau, Jianchang Lin, 2016 .

Role of thiamine in managing ifosfamide-induced encephalopathy

F. Awan, M. Hamadani, 2006, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Impact of Antiviral Prophylaxis Duration On Varicella Zoster Virus Infection Rates in Recipients of Autologous Hematopoietic Cell Transplantation

A. Kanate, M. Hamadani, M. Craig, 2013 .

Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma

C. Hofmeister, D. Benson, S. Devine, 2010, Leukemia & lymphoma.

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

J. Radford, S. Horwitz, J. Wuerthner, 2018, Blood.

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

L. Gordon, J. Winter, A. Evens, 2020 .

Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit

K. Ahn, M. Kharfan-Dabaja, A. Herrera, 2022, Haematologica.

Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab

B. Cheson, T. Kipps, A. Cuneo, 2013, Journal of Immunotherapy for Cancer.

Autologous Transplantation (autoHCT) is Associated with Improved Overall Survival (OS) in Follicular Lymphoma (FL) Patients (Pts) Experiencing Early Therapy Failure after Frontline Chemo-Immunotherapy: A National Lymphocare Study (NLCS) & CIBMTR Analysis

Sonali M. Smith, J. Friedberg, K. Ahn, 2017 .

ASTCT Clinical practice recommendations for transplant and cellular therapies in diffuse large B-cell lymphoma.

F. Awan, M. Perales, L. Lekakis, 2023, Transplantation and cellular therapy.

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

M. Dhodapkar, P. Westervelt, M. Perales, 2023, eClinicalMedicine.

Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study.

S. Forman, J. Chavez, B. Shah, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

P. Hari, D. Schneider, N. Shah, 2021, Blood.

Cost and Efficacy of Upfront Plerixafor Versus a “Just-in-Time” (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization

S. Wen, K. Watkins, A. Kanate, 2014 .

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

A. Hui, S. Lonial, J. Laubach, 2014 .

Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.

P. Hari, R. Orentas, A. Worden, 2019, Journal of Clinical Oncology.

Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease

P. Hari, N. Shah, M. Hamadani, 2019, Leukemia & lymphoma.

Early mortality in patients with acute myelogenous leukemia treated in teaching versus non‐teaching hospitals: A large database analysis

P. Hari, S. Tarima, M. Hamadani, 2017, American journal of hematology.

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

R. Varadhan, C. Huff, M. Perales, 2023, The New England journal of medicine.

Bridging the gap: Early transition and hybrid models of care to improve access to CAR-T cell therapy.

Hamza Hashmi, M. Hamadani, Zahra Mahmoudjafari, 2023, Transplantation and cellular therapy.

Infected atrial myxoma

G. Voskuhl, M. Hamadani, A. Awab, 2006, The Medical journal of Australia.

Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.

S. Wen, A. Kanate, M. Hamadani, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182].

P. Hari, M. Pasquini, M. Horowitz, 2021, Transplantation and Cellular Therapy.

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

A. Desai, A. Harrington, M. Hamadani, 2022, Blood.

A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies

D. Miklos, F. Galimi, S. Neelapu, 2022, Transplantation and Cellular Therapy.

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2

D. Miklos, F. Galimi, S. Neelapu, 2021, Blood.

HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL).

R. Advani, K. Savage, J. Radford, 2022, Clinical Lymphoma, Myeloma & Leukemia.

HODGKIN LYMPHOMA: CURE AND OPTIMAL SURVIVORSHIP

M. Hamadani, N. Epperla, 2021 .

Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age

P. Hari, M. Hamadani, L. Michaelis, 2014, Expert review of hematology.

Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.

F. Awan, K. Ahn, M. Scordo, 2023, Bone marrow transplantation.

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

J. Cerhan, J. Leonard, A. Feldman, 2022, Blood advances.

Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma

P. Hari, D. Schneider, N. Shah, 2022, Blood.

Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?

N. Shah, M. Hamadani, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy.

M. Perales, Z. DeFilipp, B. Hamilton, 2023, Transplantation and cellular therapy.

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

N. Ghosh, Kwang Woo Ahn, A. Sureda, 2019, Blood.

LONG‐TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS‐2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

J. Radford, K. Ardeshna, A. Stathis, 2023, Hematological Oncology.

CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling

Serafino Pantano, K. Havenith, J. Boni, 2022, Blood.

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

C. Carlo-Stella, M. Hamadani, Eleonora Calabretta, 2022, Blood.

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study.

J. Radford, K. Ardeshna, A. Stathis, 2023, Haematologica.

Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells.

G. Opiteck, V. Kaimal, Thomas Pertel, 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, A. Stathis, 2019, Blood.

Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter?

M. Hamadani, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

K. Savage, J. Radford, S. Ansell, 2021, Hematological Oncology.

PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5

C. Carlo-Stella, M. Hamadani, D. Ungar, 2021, Hematological Oncology.

Propylene glycol (PG)-free melphalan versus PG-melphalan as conditioning for autologous hematopoietic cell transplantation for myeloma.

P. Hari, M. Pasquini, A. Szabo, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study

Michael L. Wang, I. Lossos, C. Reeder, 2016 .

Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia

F. Awan, M. Hamadani, 2009, Hematological Oncology.

Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta‐analysis

B. Djulbegovic, J. Lancet, H. Fernandez, 2013, British Journal of Haematology.

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

Sonali M. Smith, P. Hari, P. Armand, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Sonali M. Smith, M. Perales, R. Gale, 2016, Blood.

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

J. Cortes, M. Aljurf, J. Szer, 2013, Blood.

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.

M. Mohty, M. Kharfan-Dabaja, M. Hamadani, 2011, Cancer control : journal of the Moffitt Cancer Center.

Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients.

A. D’Souza, N. Shah, M. Hamadani, 2022, Clinical lymphoma, myeloma & leukemia.

M. Hamadani, M. Craig, Michael Sweet, 2012, American journal of infection control.

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

M. Perales, Richard J. Jones, J. Bolaños-Meade, 2023, The New England journal of medicine.

Feasibility of Allogeneic Peripheral Blood Stem Cell Transplantation (Allo-SCT) Following Reduced Intensity Conditioning (RIC) in HIV+ Patients with Hematological Malignancies

R. Baiocchi, K. Blum, D. Benson, 2009 .

Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?

M. Hamadani, T. Fenske, N. Epperla, 2015, Bone Marrow Transplantation.

Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis.

M. Hamadani, D. Slain, M. Craig, 2012, International journal of antimicrobial agents.

Incidence and survival trends in mantle cell lymphoma

L. Costa, M. Hamadani, T. Fenske, 2018, British journal of haematology.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

S. Montoto, Sonali M. Smith, D. Maloney, 2015, Biology of Blood and Marrow Transplantation.

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis.

Sonali M. Smith, J. Bolaños-Meade, Z. DeFilipp, 2018, Blood advances.

Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis Is an Effective Surveillance Tool in Patients with Mantle Cell Lymphoma

N. Shah, M. Hamadani, T. Fenske, 2022, Blood.

Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: A consensus project of ASBMT, CIBMTR and LWP-EBMT.

M. Perales, B. Savani, A. Moskowitz, 2022 .

PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.

S. Montoto, D. Blaise, P. Dreger, 2019, Blood advances.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation

W. Saber, M. Hamadani, T. Fenske, 2024, Bone marrow transplantation.

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

B. Cheson, T. Kipps, M. Federico, 2013 .

Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL‐102): A phase 1 study

J. Sancho, M. Hutchings, P. Langmuir, 2023, Hematological oncology.

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan‐based reduced toxicity conditioning

C. Hofmeister, R. Garzon, G. Phillips, 2011, Hematological oncology.

Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study

L. Gordon, J. Braverman, Shien Guo, 2023, Haematologica.

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis.

A. Krishnan, S. Lonial, R. Vij, 2011, Blood.

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

C. Turtle, P. Reagan, P. Hematti, 2022 .

Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients

R. Turner, S. Wen, M. Hamadani, 2016, Antimicrobial Agents and Chemotherapy.

False-Negative PET Scan With Bronchioloalveolar Carcinoma: An Important Diagnostic Caveat

M. Hamadani, M. Peyton, B. Brown, 2007, The American journal of the medical sciences.

Bispecific antibodies in the treatment of Relapsed/Refractory large B-cell lymphoma.

M. Hamadani, F. Furqan, Gulrayz Ahmed, 2024, Expert review of anticancer therapy.

A Phase I/2 Study of Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis after Allogeneic Transplantation (alloHCT).

P. Hari, M. Pasquini, B. Shaw, 2019, Biology of Blood and Marrow Transplantation.

Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation

A. Szabo, A. Cashen, N. Shah, 2018, Blood.